Miller, Peter G.
Sathappa, Murugappan
Moroco, Jamie A. http://orcid.org/0000-0001-8250-5923
Jiang, Wei
Qian, Yue
Iqbal, Sumaiya http://orcid.org/0000-0001-7700-4374
Guo, Qi
Giacomelli, Andrew O. http://orcid.org/0000-0003-2109-0458
Shaw, Subrata
Vernier, Camille
Bajrami, Besnik
Yang, Xiaoping http://orcid.org/0000-0002-6811-4915
Raffier, Cerise
Sperling, Adam S. http://orcid.org/0000-0002-9369-4413
Gibson, Christopher J. http://orcid.org/0000-0002-3700-5310
Kahn, Josephine
Jin, Cyrus
Ranaghan, Matthew http://orcid.org/0000-0003-3572-5127
Caliman, Alisha
Brousseau, Merissa
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Lintner, Robert
Piccioni, Federica
Campbell, Arthur J.
Root, David E. http://orcid.org/0000-0001-5122-861X
Garvie, Colin W.
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01HL082945)
Article History
Received: 6 October 2021
Accepted: 2 May 2022
First Online: 30 June 2022
Competing interests
: In the past 3 years, Dr. Miller has received consulting fees from Foundation Medicine. B.L.E. has received research funding from Celgene, Deerfield, Novartis, and Calico and consulting fees from GRAIL. He is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, TenSixteen Bio, Skyhawk Therapeutics, and Exo Therapeutics. E.S.F. is a founder, science advisory board (SAB) member, and equity holder in Civetta Therapeutics, Jengu Therapeutics (board member), Neomorph Inc and an equity holder in C4 Therapeutics. E.S.F. is a consultant to Novartis, Sanofi, EcoR1 capital, Avilar and Deerfield. The Fischer lab receives or has received research funding from Astellas, Novartis, Voronoi, Ajax, and Deerfield. This work was financially supported by Deerfield Ventures; no employees of Deerfield Ventures were involved with the experimental design, experimental execution, data interpretation, figure generation, or manuscript preparation. The remaining authors declare no competing interest.